0932 ET - Eli Lilly is slightly higher is early trading after another blowout quarter driven by GLP-1 drugs. 4Q revenue rises 45% to $13.53 billion. Revenue from new products climbs by $3.15 billion to $5.64 billion, driven Zepbound and Mounjaro. Lilly's fortunes echo those of Danish rival Novo Nordisk, which sold$4.71 billion of its Ozempic drug in 4Q. Lilly shares have more than quintupled in the last five years. Rival drug makers, such as Novartis, have admitted hunting for obesity drugs of their own. Lilly and Novo have major first-mover advantage, with smaller players such as Viking Therapeutics still playing catchup. Anya Schiess, a partner at JPMorgan's asset management unit, is among those who have predicted GLP-1s will be the best-selling class of drugs yet. (rob.curran@dowjones.com)
(END) Dow Jones Newswires
February 06, 2025 09:32 ET (14:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。